Abstract
BIOITALEE aims to study circulating tumor DNA (ctDNA) alterations, their evolution and association with clinical outcome in patients (pts) receiving ribociclib+letrozole as 1st-line treatment for aBC. Here we report the analysis of baseline liquid biopsy (LB) and tumor tissue samples (TS), and their comparison.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
